Baudax Bio Inc. [NASDAQ: BXRX] gained 6.25% or 0.1 points to close at $1.70 with a heavy trading volume of 32654762 shares. The company report on February 9, 2021 that Baudax Bio Announces $17.6 Million Offering Priced At-the-Market under Nasdaq Rules.
Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) announced that it has entered into a definitive agreement with institutional and accredited investors for the purchase and sale of an aggregate of 11,000,000 shares of common stock at a purchase price of $1.60 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 10, 2021, subject to the satisfaction of customary closing conditions.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
It opened the trading session at $1.77, the shares rose to $2.11 and dropped to $1.65, the range by which the price of stock traded the whole day. The daily chart for BXRX points out that the company has recorded -50.58% loss over the past six months. However, it is still -75.26% lower than its most recent low trading price.
If we look at the average trading volume of 4.33M shares, BXRX reached to a volume of 32654762 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Baudax Bio Inc. [BXRX]:
JMP Securities have made an estimate for Baudax Bio Inc. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on May 15, 2020.
The Average True Range (ATR) for Baudax Bio Inc. is set at 0.17, with the Price to Sales ratio for BXRX stock in the period of the last 12 months amounting to 202.13.
Trading performance analysis for BXRX stock
Baudax Bio Inc. [BXRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 28.79. With this latest performance, BXRX shares gained by 49.12% in over the last four-week period, additionally sinking by -50.58% over the last 6 months – not to mention a drop of -81.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BXRX stock in for the last two-week period is set at 68.65, with the RSI for the last a single of trading hit 73.25, and the three-weeks RSI is set at 64.20 for Baudax Bio Inc. [BXRX]. The present Moving Average for the last 50 days of trading for this stock 1.2290, while it was recorded at 1.5580 for the last single week of trading, and 2.5643 for the last 200 days.
Baudax Bio Inc. [BXRX]: A deeper dive into fundamental analysis
Reflecting on the efficiency of the workforce at the company, Baudax Bio Inc. [BXRX] managed to generate an average of -$1,302,280 per employee.Baudax Bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.50.
Baudax Bio Inc. [BXRX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Baudax Bio Inc. posted -0.78/share EPS, while the average EPS was predicted by analysts to be reported at -0.94/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 17.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BXRX.
An analysis of insider ownership at Baudax Bio Inc. [BXRX]
There are presently around $6 million, or 13.90% of BXRX stock, in the hands of institutional investors. The top three institutional holders of BXRX stocks are: NORTH RUN CAPITAL, LP with ownership of 1,009,399, which is approximately -12.42% of the company’s market cap and around 1.10% of the total institutional ownership; CORSAIR CAPITAL MANAGEMENT, L.P., holding 432,752 shares of the stock with an approximate value of $0.74 million in BXRX stocks shares; and VANGUARD GROUP INC, currently with $0.65 million in BXRX stock with ownership of nearly 0.892% of the company’s market capitalization.
Positions in Baudax Bio Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 17 institutional holders increased their position in Baudax Bio Inc. [NASDAQ:BXRX] by around 438,624 shares. Additionally, 26 investors decreased positions by around 1,169,629 shares, while 8 investors held positions by with 2,001,141 shares. The mentioned changes placed institutional holdings at 3,609,394 shares, according to the latest SEC report filing. BXRX stock had 8 new institutional investments in for a total of 327,603 shares, while 15 institutional investors sold positions of 255,477 shares during the same period.